511 results match your criteria ClinicoEconomics and Outcomes Research [Journal]


Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.

Clinicoecon Outcomes Res 2019 21;11:271-282. Epub 2019 Mar 21.

Department of Endocrinology and Clinical Nutrition, H.U. Quirón Salud Madrid & Ruber Juan Bravo, Universidad Europea de Madrid, Madrid, Spain.

Background: Compared with basal-bolus insulin therapy (insulin glargine U100 plus insulin aspart), IDegLira has been shown to be associated with similar improvements in HbA1c, with superior weight loss and reduced hypoglycemia in patients with type 2 diabetes. The present analysis evaluated the cost per patient with type 2 diabetes achieving HbA1c-focused and composite treatment targets with IDegLira and insulin glargine U100 plus insulin aspart (≤4 times daily).

Methods: The proportions of patients achieving treatment targets were obtained from the treat-to-target, non-inferiority DUAL VII study (NCT02420262). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S194719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432901PMC
March 2019
1 Read

Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression.

Clinicoecon Outcomes Res 2019 14;11:257-270. Epub 2019 Mar 14.

Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA,

Background: Patients with treatment-resistant major depressive disorder (TRD) have limited treatment options. We developed an early stage cost-effectiveness model of TRD to explore the potential value of a hypothetical monotherapy relative to the standard of care (SOC). The relative impacts of the monotherapy's three differentiating features over SOC are explored: efficacy advantage, tolerability advantage, and price premium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S181718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421973PMC

Cost-of-illness of knee osteoarthritis: potential cost savings by not undergoing arthroplasty within the first 2 years.

Clinicoecon Outcomes Res 2019 14;11:245-255. Epub 2019 Mar 14.

School of Medicine, University of California, Los Angeles, CA, USA.

Purpose: Although knee arthroplasty (KA) is the largest source of hospitalization costs for knee osteoarthritis (OA), some studies have suggested reducing the use of "low-value" interventions, such as intra-articular hyaluronic acid (HA), to lower health care costs. However, those studies fail to consider that HA has demonstrated benefits in extending time to more costly KA or avoiding KA altogether. We evaluated 1) the overall knee OA costs (direct) within a 2-year period; 2) the relative contribution of HA and KA costs; 3) the direct cost savings from HA patients not undergoing KA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S170119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421880PMC
March 2019
1 Read

Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective.

Clinicoecon Outcomes Res 2019 19;11:199-219. Epub 2019 Mar 19.

Bristol-Myers Squibb, Princeton, NJ, USA.

Objectives: The introduction of innovative, high-cost oncology treatments, coupled with mounting budgetary pressures, necessitates value trade-offs across cancer types. Defining value is critical to informing decision-making. A cost-value analysis tool was used to assess relative clinical value from a US perspective using multiple outcome metrics for a variety of metastatic cancers. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/relative-value-assessment-characte
Publisher Site
http://dx.doi.org/10.2147/CEOR.S177343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430994PMC
March 2019
4 Reads

Health-related quality of life outcomes, economic burden, and associated costs among diagnosed and undiagnosed depression patients in Japan.

Clinicoecon Outcomes Res 2019 12;11:233-243. Epub 2019 Mar 12.

Global Outcomes & Epidemiology Research, Data Sciences Institute, Takeda Pharmaceuticals International, Inc., Cambridge, MA 02139, USA.

Purpose: Depression is associated with substantial health and economic burden. This study examined the impact of diagnosed and undiagnosed depression on health-related outcomes and costs among Japanese adults.

Methods: A retrospective, observational study was conducted using 2012-2014 Japan National Health and Wellness Survey (N=83,504) data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419602PMC

Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan.

Clinicoecon Outcomes Res 2019 12;11:221-232. Epub 2019 Mar 12.

Global Outcomes and Epidemiology Research, Data Sciences Institute, Takeda Pharmaceuticals International Inc., Cambridge, MA, 02139, USA.

Purpose: Previous Japanese studies have not compared health-related quality of life (HRQoL), work productivity and activity impairment, health care resource utilization (HRU), and costs in inflammatory bowel disease (IBD) patients with non-IBD controls, leading to insufficient evidence regarding IBD's true burden. The aim of this study was to examine the impact of IBD on patient-reported outcomes and costs among Japanese adults (≥18 years).

Patients And Methods: This retrospective cross-sectional study used data from the 2012-2014 Japan National Health and Wellness Survey (N=83,505). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419598PMC
March 2019
1 Read

Reduction of direct costs in high-risk lumbar discectomy patients during the 90-day post-operative period through annular closure.

Clinicoecon Outcomes Res 2019 28;11:191-197. Epub 2019 Feb 28.

Sierra Neuroscience Institute, Los Angeles, CA, USA,

Purpose: Despite being an extremely successful procedure, recurrent disc herniation is one of the most common post-discectomy complications in the lumbar spine and contributes significant health care and socioeconomic costs. Patients with large annular defects are at a high risk for reherniation, but an annular closure device (ACD) has been designed to reduce reherniation risk in this population and may, in turn, help control direct health care costs after discectomy.

Patients And Methods: This analysis examined the 90-day post-discectomy cost estimates among ACD-treated (n=272) and control (discectomy alone; n=278) patients in a randomized controlled trial (RCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S193603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400234PMC
February 2019
1 Read

Health care utilization and costs following amplified versus non-amplified molecular probe testing for symptomatic patients with suspected vulvovaginitis: a US commercial payer population.

Clinicoecon Outcomes Res 2019 20;11:179-189. Epub 2019 Feb 20.

Center for Esoteric Testing, Laboratory Corporation of America Holdings, Burlington, NC, USA.

Background: Vulvovaginitis (VV) is a common reason women seek medical attention in the USA. Both the non-specific clinical presentation and risk of preterm labor or delivery necessitate accurate identification of the causative agents to guide appropriate therapy. The diagnostic accuracy of amplified molecular probe testing (AMP) has been shown to exceed that of non-amplified molecular probe (NAMP) by 20%-25%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S191831DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388970PMC
February 2019
8 Reads

A cost-consequence analysis of parecoxib and opioids vs opioids alone for postoperative pain: Chinese perspective.

Clinicoecon Outcomes Res 2019 22;11:169-177. Epub 2019 Feb 22.

Health Economics & Outcomes Research, Pfizer Inc, New York, NY, USA.

Purpose: The use of parecoxib plus opioids for postoperative analgesia in noncardiac surgical patients seems to be cost-saving in Europe due to a reduction in opioid use and opioid-related adverse events. Given the lack of information on postoperative analgesic use in Asia, this study assessed the economic consequences of the addition of parecoxib to opioids vs opioids alone to treat postsurgical pain in China.

Methods: A cost-consequence economic evaluation assessed direct medical costs related to opioid-related clinically meaningful events (CMEs) utilizing dosing information and reported frequency of events from a Phase III, randomized, double-blind, global clinical trial (PARA-0505-069) of parecoxib plus opioids vs opioids alone for 3 days following major orthopedic, abdominal, gynecologic, or noncardiac thoracic surgery requiring general or regional anesthesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S183404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390864PMC
February 2019
2 Reads

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland.

Clinicoecon Outcomes Res 2019 15;11:159-168. Epub 2019 Feb 15.

School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Aim: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective.

Methods: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pegol, etanercept, etanercept biosimilar, golimumab, and infliximab in a biologic-naïve population over a lifetime horizon. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess the treatment response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S192235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386207PMC
February 2019
3 Reads

Catastrophic health expenditure of Vietnamese patients with gallstone diseases - a case for health insurance policy revaluation.

Clinicoecon Outcomes Res 2019 11;11:151-158. Epub 2019 Feb 11.

Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.

Purpose: Despite gallstone diseases (GSDs) being a major public health concern with both acute and chronic episodes, none of the studies in Vietnam has been conducted to investigate the household expenditure for the GSD treatment. The objective of this study was to estimate the costs of managing GSD and to explore the prevalence and determinants of catastrophic health expenditure (CHE) among Vietnamese patients.

Materials And Methods: A cross-sectional study was conducted from June 2016 to March 2017 in the Department of Hepatobiliary and Pancreatic Surgery, Viet Duc Hospital in Hanoi, Vietnam. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S191379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375106PMC
February 2019
13 Reads

Ninety-day postoperative cost in primary total hip arthroplasty: an economic model comparing surgical approaches.

Clinicoecon Outcomes Res 2019 7;11:145-149. Epub 2019 Feb 7.

DePuy Synthes, Raynham, MA 02767, USA.

Background: While primary total hip arthroplasty (THA) is a safe and effective procedure, it is unclear whether choice of surgical approach influences health care cost.

Methods: We developed an economic model in which patients receiving THA via the anterior approach (AA) by high volume anterior hip surgeons were compared to a propensity-score matched cohort of primary THA cases performed by high volume surgeons that were identified from Medicare claims (Control). Cost elements included the procedure and hospital stay, postacute care, readmission, and outpatient care through 90 days postoperatively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S196545DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370072PMC
February 2019

Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study.

Clinicoecon Outcomes Res 2019 7;11:129-144. Epub 2019 Feb 7.

BTG International, West Conshohocken, PA, USA.

Purpose: Glucarpidase (Voraxaze) is used to treat methotrexate (Mtx) toxicity in patients with delayed Mtx clearance due to impaired renal function. We examine hospital length of stay (LOS), mortality, and readmission rates for Medicare cancer patients with delayed clearance of Mtx treated with glucarpidase.

Methods: Using 2010-2017 Medicare claims data, we identified glucarpidase patients as those hospitalized with indications of select lymphomas or leukemia, inpatient chemotherapy, and glucarpidase treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S188786DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370073PMC
February 2019
3 Reads

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.

Clinicoecon Outcomes Res 2019 5;11:117-128. Epub 2019 Feb 5.

University of Nebraska Medical Center, Omaha, NE, USA.

Purpose: Treatment outcomes and direct medical costs were examined, from a US health payer perspective, of monotherapy with sarilumab 200 mg subcutaneous (SC) every 2 weeks (Q2W) vs adalimumab 40 mg SC Q2W/QW in adult patients with moderately to severely active rheumatoid arthritis who are intolerant of, inadequate responders to, or considered inappropriate candidates for continued methotrexate treatment.

Patients And Methods: Short-term analysis was based on 24-week wholesale acquisition costs of drugs and treatment response observed in the MONARCH Phase III trial (NCT02332590) per American College of Rheumatology (ACR) 20/50 criteria and European League Against Rheumatism (EULAR) Moderate/Good Disease Activity Score 28-joint count erythrocyte sedimentation rate. Long-term analysis, which also considered drug administration and routine care costs, was conducted via a 6-month decision tree and a 1- to 10-year Markov model with microsimulation of patient profiles from the MOBILITY Phase III trial (NCT01061736). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S183076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368117PMC
February 2019
3 Reads

Economic impact of pharmacist interventions on correction of stress-related mucosal damage prophylaxis practice.

Clinicoecon Outcomes Res 2019 25;11:111-116. Epub 2019 Jan 25.

Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,

Introduction: Stress-related mucosal damage (SRMD) is described as the damage of gastric mucosa due to physiological stress that is a very common complication in critically ill patients. SRMD prophylactic medications are widely prescribed all over the world, while numerous studies have revealed that a large percentage of patients admitted to non-intensive care unit (ICU) services do not need to receive these medications. The aim of this study was to determine the frequency and type of medication errors and the economic impact of clinical pharmacist intervention on stress ulcer prophylaxis (SUP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S191304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353213PMC
January 2019
3 Reads

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.

Clinicoecon Outcomes Res 2019 15;11:99-110. Epub 2019 Jan 15.

Real World Value and Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA.

Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX) therapy and to assess cost implications from the commercial perspective.

Methods: Adult RA patients with a new episode of GLM-IV or IFX treatment between Janu-ary 1, 2014 and March 31, 2016 were identified from MarketScan databases and evaluated for maintenance infusion intervals and related costs of treatment. IFX and GLM-IV patients were matched 1:1 on index medication treatment duration, gender, payer type, prior biologic use, and post-index methotrexate use. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/comparative-analysis-of-us-real-wo
Publisher Site
http://dx.doi.org/10.2147/CEOR.S185547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338107PMC
January 2019
17 Reads

Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review.

Clinicoecon Outcomes Res 2019 14;11:87-98. Epub 2019 Jan 14.

Pfizer Inc, Collegeville, PA, USA.

Background: AML is a rapidly progressing bone marrow cancer, with poor survival rates compared to other types of leukemia. IC and NIC as well as BSC treatment options are available; however, there is scant published literature on the impact of disease and treatment on the HRQoL in patients receiving NIC.

Aim: This study determined the HRQoL among NIC AML patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S187409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336133PMC
January 2019
2 Reads

Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands.

Clinicoecon Outcomes Res 2019 14;11:73-82. Epub 2019 Jan 14.

Leiden University Medical Center, Leiden, the Netherlands.

Aim: The aim of this study was to perform a cost-effectiveness analysis to establish the cost-effectiveness of sensor-augmented pump therapy (SAP) with automated insulin suspension vs continuous subcutaneous insulin infusion (CSII) alone in patients with type 1 diabetes in the Netherlands.

Patients And Methods: The analysis was performed using the IQVIA CORE Diabetes Model (CDM) in two different patient cohorts: one with suboptimal glycemic control at baseline (mean age 27 years, mean baseline HbA1c 8.0% [64 mmol/mol]) and the other at increased risk of hypoglycemic events (mean age 18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S186298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336135PMC
January 2019

Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries.

Clinicoecon Outcomes Res 2019 7;11:61-71. Epub 2019 Jan 7.

Global Outcomes and Epidemiology Research. Data Sciences Institute, Takeda Pharmaceutical International, Cambridge, MA 02139, USA.

Purpose: Multiple sclerosis (MS) imposes a huge burden on patients. This study examined the relationship between MS and health-related and economic burden in Japan; secondarily, health status was compared across patients with MS in Japan, US, and five European Union (5EU) countries (France, Germany, Italy, Spain, and UK).

Methods: A retrospective cross-sectional study was conducted using self-reported data from 2009 to 2014 Japan National Health and Wellness Survey (n=145,759). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327901PMC
January 2019
7 Reads

Impact of migraine on health care utilization and expenses in obese adults: a US population-based study.

Clinicoecon Outcomes Res 2019 31;11:51-59. Epub 2018 Dec 31.

Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.

Purpose: Migraine prevalence increases in people with obesity, and obesity may contribute to migraine chronicity. Yet, few studies examine the effect of comorbid migraine on health care utilization and expenses in obese US adults. This study aimed to identify risk factors for migraine and compare the use of health care services and expenses between migraineurs and non-migraineurs in obese US adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S189699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318707PMC
December 2018
1 Read

Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings.

Clinicoecon Outcomes Res 2019 19;11:23-49. Epub 2018 Dec 19.

US Medical Affairs, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Introduction: Direct oral anticoagulants (DOACs) have emerged as viable alternatives to traditional treatments such as vitamin K antagonists (VKAs) for venous thromboembolism (VTE). The objective of this review was to summarize evidence on the use of DOACs and VKAs to treat VTE in the US for patients transitioning from inpatient to post-discharge settings.

Materials And Methods: A systematic review of the VTE literature identified studies published in English (January 1, 2011-December 31, 2016) that reported inpatient and post-discharge treatments and discharge location. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305128PMC
December 2018
2 Reads

Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant.

Clinicoecon Outcomes Res 2019 17;11:13-22. Epub 2018 Dec 17.

Health Economics and Outcomes Research, Jazz Pharmaceuticals, Palo Alto, CA, USA,

Purpose: The study objective was to develop an economic model to assess projected costs of lost productivity associated with premature deaths due to veno-occlusive disease (VOD)/ sinusoidal obstruction syndrome (SOS) with multiorgan dysfunction (MOD) among patients in the US who underwent hematopoietic stem-cell transplant (HSCT) in 2013.

Methods: Data sources included the US Census Bureau and Department of Health, epidemiologic research organizations, and medical research literature. The model considered only lost productivity associated with premature death, with lifetime salary assumed to reflect productivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S184883DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301294PMC
December 2018
2 Reads

A US hospital budget impact analysis of a skin closure system compared with standard of care in hip and knee arthroplasty.

Clinicoecon Outcomes Res 2019 17;11:1-11. Epub 2018 Dec 17.

Cornerstone Research Group Inc., Burlington, ON, Canada,

Background: Medicare's mandatory bundle for hip and knee arthroplasty necessitates provider accountability for quality and cost of care to 90 days, and wound closure may be a key area of consideration. The DERMABOND PRINEO Skin Closure System (22 cm) combines a topical skin adhesive with a self-adhering mesh without the need for dressing changes or suture or staple removal. This study estimated the budget impact of the Skin Closure System compared to other wound closure methods for hip and knee arthroplasty. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S181630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301301PMC
December 2018
7 Reads

The number needed to treat and relevant between-trial comparisons of competing interventions.

Clinicoecon Outcomes Res 2018 14;10:865-871. Epub 2018 Dec 14.

Evidence and Value Generation, Takeda International, Deerfield, IL, USA,

The number needed to treat (NNT) is considered an intuitive as well as popular effect measure. The aims of this review were to 1) explain why we cannot compare trial-specific NNT estimates for the competing treatments evaluated in different randomized controlled trials (RCTs) and 2) outline the principles of how relative treatment effects of different trials can be compared and results can be presented as NNT, without violating the principles of valid between-trial comparisons. Our premise is that ratio measures for relative treatment effects of response outcomes are less prone to effect modification than absolute difference measures of response outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S180491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298880PMC
December 2018
3 Reads

The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings.

Clinicoecon Outcomes Res 2018 14;10:855-863. Epub 2018 Dec 14.

MedStar Washington Hospital Center, Washington, DC, USA.

Purpose: The aim of this study was to quantify the potential cost savings to Medicare of shifting the site of treatment for worsening heart failure (HF) from inpatient to outpatient (OP) settings for a subset of worsening HF episodes among the Medicare fee-for-service (FFS) population.

Materials And Methods: A cross-sectional analysis of a random 5% sample of 2014 FFS Medicare beneficiaries was conducted. Incidence and cost of worsening HF episodes in both inpatient and OP settings were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S184048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298883PMC
December 2018
3 Reads

A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions.

Clinicoecon Outcomes Res 2018 26;10:821-854. Epub 2018 Nov 26.

Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada,

Introduction: Budget impact analysis (BIA) in health care, sometimes referred to as resource impact, is the financial change in the use of health resources associated with adding a new drug to a formulary or the adoption of a new health technology. Several national and transnational organizations worldwide have updated their BIA guidelines in the past 4 years. The aim of the present review was to provide a comprehensive list of the key recommendations of BIA guidelines from different countries that may be of interest for those who wish to build or to update BIA guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S178825DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263295PMC
November 2018
1 Read

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.

Clinicoecon Outcomes Res 2018 16;10:805-819. Epub 2018 Nov 16.

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA,

Objective: To estimate the 5-year budget impact (BI) on a US health plan of introducing sarilumab - a human immunoglobulin G1 anti-IL-6 receptor α monoclonal antibody - as combination treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or monotherapy in patients with moderate-to-severe rheumatoid arthritis (RA).

Methods: BI analysis was conducted from a commercial payer perspective. Treatment-eligible populations included adult patients with moderate-to-severe RA and inadequate response (IR) to csDMARDs or tumor necrosis factor (TNF)-α inhibitors-IR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S163829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247948PMC
November 2018
2 Reads

Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.

Clinicoecon Outcomes Res 2018 14;10:791-803. Epub 2018 Nov 14.

HEOR & Data Analytics, Novo Nordisk Inc, Plainsboro, NJ, USA,

Background: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results (LEADER) clinical trial demonstrated that liraglutide added to standard-of-care (SoC) therapy for type 2 diabetes (T2D) with established cardiovascular disease (CVD) or elevated cardiovascular (CV) risk was associated with lower rates of death from CVD, nonfatal myocardial infarction (MI), or nonfatal stroke than SoC alone.

Objective: The objective of this study was to assess the cost-effectiveness (CE) and budget impact of liraglutide vs SoC in T2D patients with established CVD or elevated CV risk, over a lifetime horizon from a US managed care perspective.

Methods: A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S180067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241540PMC
November 2018
1 Read

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.

Clinicoecon Outcomes Res 2018 14;10:773-790. Epub 2018 Nov 14.

Oblikue Consulting, Barcelona, Spain,

Purpose: The aim of this study was to evaluate the cost-effectiveness of ribociclib compared to palbociclib, both in combination with letrozole, in the first-line treatment of postmenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (ABC) from the perspective of the Spanish National Health System (NHS).

Patients And Methods: Disease progression was simulated with a partitioned survival model developed from the parameterization and extrapolation of survival curves of postmenopausal women with HR+/HER2- ABC from clinical trials with ribociclib or palbociclib, both in combination with letrozole. The model was structured on the basis of three health states (progression-free, progressed disease, and death), with a 1-month cycle length and inclusion of subsequent treatments administered for disease progression, over a time horizon of 15 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S178934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241542PMC
November 2018
2 Reads

Impact of postcolectomy adhesion-related complications on healthcare utilization.

Clinicoecon Outcomes Res 2018 14;10:761-771. Epub 2018 Nov 14.

Medical Devices-Epidemiology, Johnson and Johnson, New Brunswick, NJ 08901, USA,

Objective: The objective of this study was to explore adhesion-related complications (ARCs) within 1 year after colectomy.

Methods: Using Truven MarketScan® Commercial and Medicare databases, the first inpatient colectomies during 2009-2013 (index) were identified: left, right, partial, transverse, or total. One-year continuous enrollment was required pre and postindex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241541PMC
November 2018
3 Reads

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Clinicoecon Outcomes Res 2018 12;10:747-759. Epub 2018 Nov 12.

Global Patient Outcomes and Real World Evidence International, Eli Lilly, Surrey, UK.

Background: Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer agents with similar mechanisms of action and efficacy; therefore, there is a need to evaluate their efficiency in terms of cost effectiveness.

Objective: This study evaluates the cost effectiveness of recently approved interleukin (IL)-17A antagonists, ixekizumab and secukinumab, for the treatment of moderate-to-severe plaque psoriasis from the perspective of the Spanish National Health System (NHS).

Materials And Methods: A Markov model with a lifetime horizon was developed to compare the cost effectiveness of ixekizumab vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237133PMC
November 2018
6 Reads

Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk.

Clinicoecon Outcomes Res 2018 8;10:733-745. Epub 2018 Nov 8.

Minimally Invasive Cardiothoracic Department, Istituto Clinico Sant'Ambrogio, Gruppo Ospedaliero San Donato, Milan, Italy.

Background: Meta-analyses of studies comparing transcatheter aortic valve implants (TAVIs) and sutureless aortic valve replacement (SU-AVR) show differing effectiveness and safety profiles. The approaches also differ in their surgical cost (including operating room and device).

Objective: The objective of this study was to assess the incremental cost-utility of SU-AVR vs TAVIs for the treatment of intermediate- to high-risk patients in the US, Germany, France, Italy, UK, and Australia. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/cost-utility-of-surgical-sutureles
Publisher Site
http://dx.doi.org/10.2147/CEOR.S185743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231515PMC
November 2018
16 Reads

Erratum: Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region [Corrigendum].

Authors:

Clinicoecon Outcomes Res 2018 8;10:731. Epub 2018 Nov 8.

[This corrects the article on p. 389 in vol. 10, PMID: 30087571. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S188625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231512PMC
November 2018
15 Reads

Economic analysis of pharmacist-administered influenza vaccines in Ontario, Canada.

Clinicoecon Outcomes Res 2018 24;10:655-663. Epub 2018 Oct 24.

School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, ON, Canada.

Objective: The aim of this study was to evaluate the impact of pharmacist administration of influenza vaccine in Ontario on: 1) vaccination-associated costs related to the number of people vaccinated; 2) annual influenza-related outcomes and costs; and 3) change in productivity costs.

Methods: Using available data for Ontario, the total number of vaccinations given by providers in the 2011/12 influenza season (pre) was compared to the 2013/14 influenza season (post). Vaccine costs and provider fees for administration were assigned for both periods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207261PMC
October 2018
7 Reads

Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon.

Clinicoecon Outcomes Res 2018 2;10:723-730. Epub 2018 Nov 2.

Value and Access, Biogen, Cambridge, MA, USA,

Background: Real-world outcomes from staying on an interferon beta (IFNβ) vs switching to another IFNβ could help guide treatment decisions. This study's objective was to compare outcomes of stable multiple sclerosis (MS) patients on an IFNβ who stayed on therapy vs those who switched to another IFNβ.

Methods: MS patients were identified from the Optum Insights Clinformatics Data Mart Multi-Plan who were 18-64 years old and relapse-free (stable) over 1 year while continuously being treated with an IFNβ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S163907DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219109PMC
November 2018
8 Reads

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia.

Clinicoecon Outcomes Res 2018 5;10:715-721. Epub 2018 Nov 5.

Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, Scotland, UK.

Background: Immune thrombocytopenia (ITP) is an auto-immune disorder characterized by enhanced platelet destruction and, subsequently, the potential for increased bleeding. Thrombopoietin receptor (TPO-R) agonists have recently emerged as promising therapies for ITP patients who are refractory to other treatments. While eltrombopag (EPAG) is the only TPO-R agonist US Food and Drug Administration approved for use in pediatric patients, romiplostin (ROMI) has been used in Phase III clinical studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S177338DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223346PMC
November 2018
9 Reads

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia.

Clinicoecon Outcomes Res 2018 1;10:705-713. Epub 2018 Nov 1.

William R. Lindsay Chair of Health Economics, University of Glasgow, Glasgow, Scotland, UK.

Background: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids or immunoglobulins.

Methods: A cost-consequence model was developed to evaluate the costs relative to treatment success of EPAG, ROMI, and watch and rescue (W&R) in previously treated patients. The primary endpoint assessed was severe bleeding, derived from all identified phase III registered clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S177324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219311PMC
November 2018
13 Reads

Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease.

Clinicoecon Outcomes Res 2018 31;10:693-703. Epub 2018 Oct 31.

Regenstrief Center for Healthcare Engineering and Center for Health Outcomes Research and Policy, College of Pharmacy, Purdue University, West Lafayette, IN, USA,

Purpose: Incremental health care resource utilization and expenditures associated with autosomal dominant polycystic kidney disease (ADPKD) were estimated.

Methods: Study data were from a large administrative claims database. Individuals aged 18 years or older enrolled in tracked health plans for 12 months from April 1, 2011 through March 31, 2012, and with an International Classification of Disease, Ninth Revision, Clinical Modification diagnosis code for "polycystic kidney, autosomal dominant" (753. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216970PMC
October 2018
21 Reads

Burden of cancer pain in developing countries: a narrative literature review.

Clinicoecon Outcomes Res 2018 2;10:675-691. Epub 2018 Nov 2.

Mundipharma Pte Ltd., Singapore, Singapore,

Cancer pain is one of the most common, feared, debilitating, and often undertreated symptoms among cancer patients. It needs attention since it has a significant impact on the quality of life (QoL) of the patients. Also, since cancer has emerged as a major health problem in developing countries, there is a need to strengthen preventive strategies for effective cancer pain management and provide comfort to cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S181192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219110PMC
November 2018
15 Reads

Economic benefits of implementing patient-centered medical home among patients with hypertension.

Clinicoecon Outcomes Res 2018 31;10:665-673. Epub 2018 Oct 31.

Department of Clinical Pharmacy, College of Pharmacy, Qassim University, Buraydah, Qassim, Saudi Arabia.

Introduction: Despite the strong evidence of an association between adoption of the patient-centered medical home (PCMH) and improved clinical outcomes among patients with hypertension, evidence for associations between the PCMH and health care utilization and cost reduction within the general adult population with hypertension is less developed.

Objective: This study was designed to examine the effect of PCMH on health service expenditures and utilization in a national sample of the US adult population who were diagnosed with hypertension.

Methods: The 2010-2015 Medical Expenditure Panel Survey data were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216964PMC
October 2018
25 Reads

Health-related outcomes and economic burden in Japan: focus on inflammatory bowel disease, multiple sclerosis, and depression.

Authors:
Kaoru Yamabe

Clinicoecon Outcomes Res 2018 23;10:653-654. Epub 2018 Oct 23.

Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Chuou-ku, Tokyo, Japan,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S184289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203106PMC
October 2018
2 Reads

Impact of antiepileptic-drug treatment burden on health-care-resource utilization and costs.

Clinicoecon Outcomes Res 2018 16;10:619-627. Epub 2018 Oct 16.

RTI Health Solutions, Research Triangle Park, NC 27709, USA.

Background: Complex titration requirements and dosing of antiepileptic drugs (AEDs) may pose a significant treatment burden for patients with epilepsy. This study evaluated health-care-resource utilization (HCRU) rates and costs by treatment burden, defined as number of daily pills and dosing frequency, among managed-care enrollees with epilepsy who initiated AED monotherapy.

Methods: This retrospective longitudinal study examined administrative HC-claim data in patients aged ≥18 years with two or more pharmacy claims for an AED and two or more medical claims for epilepsy or afebrile convulsion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S180913DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201987PMC
October 2018
13 Reads

Sacroiliac joint fusion health care cost comparison prior to and following surgery: an administrative claims analysis.

Clinicoecon Outcomes Res 2018 17;10:643-651. Epub 2018 Oct 17.

Department of Orthopedic Surgery, University of Minnesota, Minneapolis, MN, USA.

Purpose: To assess real-world expenditures on surgical and non-surgical treatment for sacroiliac joint (SIJ) pain by comparing direct health care costs before and after surgery in patients who underwent an SIJ fusion (SIJF) procedure.

Materials And Methods: This retrospective observational study examined administrative claims data (January 1, 2010 to February 28, 2017) for adult commercial health plan members with a medical claim for SIJF. Identified patients were included if they had continuous enrollment in the health plan for 12 months pre-SIJF (baseline period) and 12 months post-SIJF (follow-up period). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S177094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198879PMC
October 2018
2 Reads

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure.

Clinicoecon Outcomes Res 2018 17;10:629-641. Epub 2018 Oct 17.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Purpose: The purpose of this study was to evaluate the economic burden of frontline failure (FLF) among classical Hodgkin lymphoma (HL) patients during and after treatment.

Patients And Methods: The population consisted of adult HL patients identified from January 2010 through September 2015 without any other primary cancer prior to HL diagnosis, who also had a frontline (FL) regimen indicative of curative intent. Patients were characterized as FLF (those who restart, switch to any chemotherapy; had a hematopoietic stem cell transplant; or newly initiated radiation therapy [RT] after discontinuing FL) or non-FLF (those not considered as FLF). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/real-world-analysis-of-cost-health
Publisher Site
http://dx.doi.org/10.2147/CEOR.S178649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198880PMC
October 2018
13 Reads

A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK) lowering cardiovascular disease risk.

Clinicoecon Outcomes Res 2018 8;10:601-609. Epub 2018 Oct 8.

Hypertension Research Centre, University of Naples Federico II, Naples, Italy.

Context: Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk.

Objective: To evaluate the cost and effectiveness of LopiGLIK (LOPI) in lowering LDL-C and CVD risk. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/a-single-blind-multicenter-randomi
Publisher Site
http://dx.doi.org/10.2147/CEOR.S172838DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181120PMC
October 2018
8 Reads

The role of a best practice alert in the electronic medical record in reducing repetitive lab tests.

Clinicoecon Outcomes Res 2018 8;10:611-618. Epub 2018 Oct 8.

Department of Pathology, Immunology, & Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.

Background: The recommendations of the American Board of Internal Medicine Foundation's "Choosing Wisely" initiative recognize the importance of improving the appropriateness of testing behavior and reducing the number of duplicate laboratory tests.

Objective: To assess the effectiveness of an electronic medical record Best Practice Alert (BPA or "pop up") intervention aimed at reducing duplicate laboratory tests and hospital costs.

Design: Comparison of the number of duplicated laboratory tests performed on inpatients before and after the intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167499DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181108PMC
October 2018
1 Read

Comparison of real-world clinical and economic outcomes between the ThermoCool SF and ThermoCool catheters in patients undergoing radiofrequency catheter ablation for atrial fibrillation.

Clinicoecon Outcomes Res 2018 4;10:587-599. Epub 2018 Oct 4.

Johnson & Johnson Medical Device Epidemiology, New Brunswick, NJ, USA,

Introduction: This study evaluated the real-world clinical and economic outcomes associated with the use of the ThermoCool Surround Flow (SF) and ThermoCool catheters in atrial fibrillation (AF) ablation.

Methods: Adults with AF who underwent catheter ablation between January 1, 2013, and December 31, 2016, in a hospital outpatient setting were identified from the Premier Healthcare Database. Using a search strategy of hospital-charge descriptors, patients were classified into two mutually exclusive groups: ThermoCool SF catheter and ThermoCool catheter. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/comparison-of-real-world-clinical-
Publisher Site
http://dx.doi.org/10.2147/CEOR.S180125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181087PMC
October 2018
4 Reads

Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness.

Clinicoecon Outcomes Res 2018 2;10:573-585. Epub 2018 Oct 2.

Health Economics and Outcomes Management, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.

Background: New digital technologies offer providers the promise of more accurately tracking patients' medication adherence. It is unclear, however, whether access to such information will affect provider treatment decisions in the real world.

Methods: Using prescriber-reported information on patient non-compliance from health insurance claims data between 2008 and 2014, we examined whether prescribers' knowledge of non-compliance was associated with different prescribing patterns for patients with serious mental illness (SMI). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/does-knowledge-of-patient-non-comp
Publisher Site
http://dx.doi.org/10.2147/CEOR.S175877DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173173PMC
October 2018
25 Reads

Societal costs due to meningococcal disease: a national registry-based study.

Clinicoecon Outcomes Res 2018 2;10:563-572. Epub 2018 Oct 2.

Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Purpose: Limited detailed evidence exists on the societal costs of meningococcal disease. The objective of this study was to estimate the average 5-year societal cost of events attributable to meningococcal disease in Denmark.

Methods: The study was based on the nationwide Danish registries. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/societal-costs-due-to-meningococca
Publisher Site
http://dx.doi.org/10.2147/CEOR.S175835DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173181PMC
October 2018
16 Reads